Evidence map›Paper›PMID 34679613›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection.

Václav Šimánek, Ladislav Pecen, Hana Řezáčková, Ondřej Topolčan, Karel Fajfrlík, Dalibor Sedláček, Robin Šín, Monika Bludovská, Petr Pazdiora, David Slouka and 1 more

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Václav ŠimánekDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.
Ladislav PecenDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.
Hana ŘezáčkováDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.ORCID 0000-0001-6016-0207
Ondřej TopolčanDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.
Karel FajfrlíkDepartment of Microbiology, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.
Dalibor SedláčekDepartment of Infectious Diseases and Travel Medicine, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.ORCID 0000-0003-4711-6679
Robin ŠínDepartment of Infectious Diseases and Travel Medicine, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.ORCID 0000-0003-4410-9078
Monika BludovskáFaculty of Medicine in Pilsen, Institute of Pharmacology and Toxicology, Charles University, 323 00 Pilsen, Czech Republic.
Petr PazdioraFaculty of Medicine in Pilsen, Institute of Epidemiology, Charles University, 301 00 Pilsen, Czech Republic.ORCID 0000-0001-8414-3874
David SloukaDepartment of Otorhinolaryngology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, 309 55 Pilsen, Czech Republic.ORCID 0000-0002-3988-7898
Radek KučeraDepartment of Immunochemistry Diagnostics, University Hospital in Pilsen, 309 55 Pilsen, Czech Republic.ORCID 0000-0002-2739-2302

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1-3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection.

Indexed as

antibodyCOVID-19immunoassaynucleocapsid proteinSARS-CoV-2serological diagnosticstime period

Identifiers

PMID34679613
PMCPMC8534661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.